Table 3

Univariate and multivariate analysis for progression-free survival

Variables		Univariate	Multivariate
			Full model 1*	Full model 2†	Reduced model
		P value	P value	P value	HR	95% CI	P value
Age (years)	<67	0.482
Age (years)	≥67
Sex	Male	0.416
Sex	Female
ECOG PS		0.504
	0	0.250
	1	0.678
	≥2	Ref.
IMDC risk		0.324	0.622	0.428
	Favorable	0.176	0.805	0.967
	Intermediate	0.903	0.498	0.276
	Poor	Ref.	Ref.	Ref.
Histology	Clear cell	0.465
Histology	Non-clear cell
Liver metastases	Presence	0.901
Liver metastases	Absence
Brain metastases	Presence	0.437
Brain metastases	Absence
Previous nephrectomy	Presence	0.830
Previous nephrectomy	Absence
No. of previous systemic therapies		0.640
	1	0.611
	2	0.694
	≥3	Ref.
Baseline LDH (IU/L)	<333	0.155
Baseline LDH (IU/L)	≥333
Baseline NLR	<3.0	0.125
Baseline NLR	≥3.0
Baseline CRP level (mg/L)	<10	0.078	0.403	–
Baseline CRP level (mg/L)	≥10
Baseline CRP level (mg/L)	Continuous	0.071	–	0.067
Early CRP kinetics		0.004	0.008	0.003			0.004
	CRP flare-responder	<0.001	0.003	0.002	0.13	0.02–0.47	<0.001
	CRP responder	0.067	0.032	0.015	0.45	0.18–1.06	0.067
	Non-CRP responder	Ref.	Ref.	Ref.	Ref.

*Baseline CRP level was used for a categorical analysis.
†Baseline CRP level was evaluated as a continuous variable.
CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; No., number; ref., reference.